[

zydus cadila

]
The Drugs Controller General of India (DCGI) gave its nod to the ZyCoV-D Covid-19 vaccine earlier on August 20.

'Plans afoot to add ZyCoV-D Covid-19 vaccine to national vaccination programme'

Written by Srivatsan K C | Edited by Avik Roy, Hindustan Times, New Delhi
PUBLISHED ON SEP 14, 2021 04:25 PM IST
“The discussion on its pricing is ongoing, a decision will be taken soon. We are looking to include this vaccine in the national vaccination program,” Dr Paul said.
Secretary, Ministry of Health & Family Welfare, Rajesh Bhushan addresses a press conference on the actions taken, preparedness and updates on Covid-19 (including vaccination), in New Delhi on Thursday. (PTI)
Secretary, Ministry of Health & Family Welfare, Rajesh Bhushan addresses a press conference on the actions taken, preparedness and updates on Covid-19 (including vaccination), in New Delhi on Thursday. (PTI)

Zydus vaccine for kids likely to be available by Oct, says Centre

By Rhythma Kaul, New Delhi
UPDATED ON AUG 27, 2021 02:13 AM IST
It still isn’t clear whether the vaccine will form part of the country’s ongoing drive to vaccinate all adults by the end of the year, or be reserved for the use of children
ZyCov-D became the sixth vaccine to be approved in India.(Representational image)
ZyCov-D became the sixth vaccine to be approved in India.(Representational image)

When will ZyCov-D shot be available for children under 12?

Written by Srivatsan K C | Edited by Poulomi Ghosh, Hindustan Times, New Delhi
PUBLISHED ON AUG 21, 2021 08:37 PM IST
“In the younger age group, we have not started them yet. We are working now with the regulators to work on a program to do a study for the younger age group as well," Zydus Group MD Dr Sharvil Patel said.
Representative Image
Representative Image

Zydus Cadila says will begin supply of its Covid-19 vaccine in mid-September

By hindustantimes.com, New Delhi
PUBLISHED ON AUG 21, 2021 03:00 PM IST
ZyCoV-D on Friday became India's second indigenous Covid-19 vaccine, and the sixth overall.
Zydus Cadila vaccine will be a three-dose vaccine and will have to be administered intradermally.(File Photo)
Zydus Cadila vaccine will be a three-dose vaccine and will have to be administered intradermally.(File Photo)

'Momentous feat': PM Modi on Zydus Cadila’s Covid vaccine getting approval

By hindustantimes.com | Written by Ayshee Bhaduri | Edited by Poulomi Ghosh, Hindustan Times, New Delhi
PUBLISHED ON AUG 20, 2021 10:36 PM IST
  • Zydus Cadila’s Covid-19 vaccine, ZyCoV-D, is the world's first DNA-based vaccine against the coronavirus which when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response
ZyCoV-D is a first of its kind DNA vaccine that produces the spike protein of the SARS-CoV-2 to elicit an immune response.(Reuters file photo. Representative image)
ZyCoV-D is a first of its kind DNA vaccine that produces the spike protein of the SARS-CoV-2 to elicit an immune response.(Reuters file photo. Representative image)

Zydus Cadila's 3-dose vaccine gets approval, 1st jab for children in India

By hindustantimes.com | Written by Ayshee Bhaduri | Edited by Poulomi Ghosh, Hindustan Times, New Delhi
PUBLISHED ON AUG 20, 2021 06:22 PM IST
  • If approved, ZyCoV-D will be India’s second indigenous coronavirus vaccine after Covaxin, and the sixth vaccine to be approved in the country so far
Zydus Cadila vaccine will be a three-dose vaccine and will have to be administered intradermally.(File Photo)
Zydus Cadila vaccine will be a three-dose vaccine and will have to be administered intradermally.(File Photo)

Zydus Cadila's Covid-19 vaccine likely to get emergency approval by this week

By hindustantimes.com, New Delhi
PUBLISHED ON AUG 09, 2021 01:39 PM IST
Zydus Cadila is planning to manufacture 100-120 million doses of the vaccine annually.
A Covid-19 vaccination centre in Kolkata (ANI/used only for representative purpose)
A Covid-19 vaccination centre in Kolkata (ANI/used only for representative purpose)

Zydus Cadila submits additional data on its Covid-19 vaccine to DCGI: Report

By hindustantimes.com | Written by Karan Manral
PUBLISHED ON JUL 27, 2021 08:33 PM IST
The Ahmedabad-based firm's vaccine candidate, ZyCoV-D, is expected to be approved in August.
Zydus Cadila, which is developing DNA vaccines for Covid-19, has concluded its clinical trial for children between the ages of 12 and 18 years of age and is awaiting statutory permission.(Reuters)
Zydus Cadila, which is developing DNA vaccines for Covid-19, has concluded its clinical trial for children between the ages of 12 and 18 years of age and is awaiting statutory permission.(Reuters)

Vaccine for kids to be available soon: Centre

By Richa Banka, Hindustan Times, New Delhi
UPDATED ON JUL 17, 2021 04:53 AM IST
The government told the court that the Drug Controller General of India has permitted Bharat Biotech to conduct clinical trials on children between the ages of 2 and 18 for its vaccine, Covaxin.
NITI Aayog member Dr VK Paul (File Photo)
NITI Aayog member Dr VK Paul (File Photo)

'Need more data to make Zydus' anti-Covid shot available for children': VK Paul

By hindustantimes.com | Written by Karan Manral, New Delhi
UPDATED ON JUL 16, 2021 07:22 PM IST
Ahmedabad-based Zydus Cadila applied to DCGI on July 1, seeking emergency use authorisation for its vaccine to be administered to those above the age of 12.
A vaccine against the coronavirus disease (Covid-19) for children that is being developed by Gujarat-based pharmaceutical company Zydus Cadila may not be available soon(File Photo)
A vaccine against the coronavirus disease (Covid-19) for children that is being developed by Gujarat-based pharmaceutical company Zydus Cadila may not be available soon(File Photo)

News updates from HT: Zydus Cadila's vaccine for kids may not be available soon

By hindustantimes.com, Hindustan Times, New Delhi
PUBLISHED ON JUL 12, 2021 12:50 PM IST
  • Here are today’s top news, analysis, and opinion. Know all about the latest news and other news updates from Hindustan Times.
Zydus Cadila has planned to annually manufacture 100-120 million doses of ZyCoV-D, its DNA-based Covid-19 vaccine.(Reuters )
Zydus Cadila has planned to annually manufacture 100-120 million doses of ZyCoV-D, its DNA-based Covid-19 vaccine.(Reuters )

‘Efficacy 67%’: Zydus seeks nod for vaccine

By Rhythma Kaul, New Delhi
UPDATED ON JUL 02, 2021 12:19 AM IST
Zydus Cadila said that this is the first coronavirus vaccine using a DNA plasmid in advanced trials, and the first in India to be tested in a large group of adolescents.
Zycov-D was tested in a three-dose regimen, with the second and third given 21 and 56 days after the first. But the company said it has also evaluated a two-dose regimen and found similar results, hinting at plans to make it a two-dose regimen.(File Photo)
Zycov-D was tested in a three-dose regimen, with the second and third given 21 and 56 days after the first. But the company said it has also evaluated a two-dose regimen and found similar results, hinting at plans to make it a two-dose regimen.(File Photo)

What is ZyCov-D, world’s first DNA vaccine for Covid?

By HT Correspondent, New Delhi
UPDATED ON JUL 02, 2021 12:48 AM IST
If approved, it will be the fifth vaccine against coronavirus to be approved in India, after Covishield, Covaxin, Sputnik V and the Moderna shot.
Zydus Cadila conducted late-stage trials in more than 28,000 volunteers nationwide, with nearly 1,000 volunteers belonging to the age group of 12 to 18.(Reuters/Representative Image)
Zydus Cadila conducted late-stage trials in more than 28,000 volunteers nationwide, with nearly 1,000 volunteers belonging to the age group of 12 to 18.(Reuters/Representative Image)

Zydus Cadila seeks emergency approval for its vaccine. All you need to know

By hindustantimes.com | Edited by Ayshee Bhaduri, Hindustan Times, New Delhi
PUBLISHED ON JUL 01, 2021 02:40 PM IST
  • Zydus said, if approved, ZyCoV-D will be the world's first DNA vaccine
Covid-19 vaccine
Covid-19 vaccine

Zydus Cadila seeks DCGI nod for emergency use of its DNA vaccine for 12+ age

By hindustantimes.com | Written by Joydeep Bose
PUBLISHED ON JUL 01, 2021 08:45 AM IST
Zydus Cadila has planned to annually manufacture 100-120 million doses of ZyCoV-D, its DNA-based Covid-19 vaccine.
A nurse fills a syringe with vaccine at a center in New Delhi(AFP)
A nurse fills a syringe with vaccine at a center in New Delhi(AFP)

News updates from HT: Zydus Cadila Covid vaccine for teens to be out by August

By hindustantimes.com, Hindustan Times, New Delhi
UPDATED ON JUN 27, 2021 09:01 PM IST
  • Here are today’s top news, analysis, and opinion. Know all about the latest news and other news updates from Hindustan Times.
Zydus Cadila’s ZyCoV-D will be the first DNA vaccine in the world and will be India’s fourth addition to the vaccine arsenal.(Reuters/Representative Image)
Zydus Cadila’s ZyCoV-D will be the first DNA vaccine in the world and will be India’s fourth addition to the vaccine arsenal.(Reuters/Representative Image)

Zydus Cadila’s Covid vaccine for children above 12 years could be out in August

By hindustantimes.com | Written by Shankhyaneel Sarkar | Edited by Poulomi Ghosh, Hindustan Times, New Delhi
UPDATED ON JUN 27, 2021 08:45 PM IST
  • National Technical Advisory Group on Immunisation (NTAGI) chairman Dr Arora also said that the trials are likely to be completed by July-end.
The Covid jab is also being tested on children in the age group of 12-18 years, apart from adults, according to Zydus.(Reuters file photo. Representative image)
The Covid jab is also being tested on children in the age group of 12-18 years, apart from adults, according to Zydus.(Reuters file photo. Representative image)

Zydus Cadila to seek emergency approval for its Covid vaccine: Details

By hindustantimes.com | Written by Deepali Sharma | Edited by Amit Chaturvedi, Hindustan Times, New Delhi
PUBLISHED ON JUN 23, 2021 12:16 PM IST
  • According to Zydus Cadila, the three doses of Zycov-D are to be administered at day 0, day 28 and day 56.
Currently, the country’s vaccination programme is using the Oxford-AstraZeneca vaccine, locally manufactured as Covishield, Bharat Biotech’s Covaxin, and Russian vaccine Sputnik V.(REUTERS PHOTO.)
Currently, the country’s vaccination programme is using the Oxford-AstraZeneca vaccine, locally manufactured as Covishield, Bharat Biotech’s Covaxin, and Russian vaccine Sputnik V.(REUTERS PHOTO.)

Zydus Cadila set to seek nod for its Covid vaccine

By HT Correspondent, New Delhi
UPDATED ON JUN 20, 2021 04:24 AM IST
  • If approved by the Drugs Controller General of India, it will become the fourth vaccine to be cleared for use against the viral infection in India
Zydus said that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild Covid-19.(Reuters file photo. Representative image)
Zydus said that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild Covid-19.(Reuters file photo. Representative image)

Zydus Cadila gets nod for clinical trials of antibodies cocktail: Report

ANI | , New Delhi
PUBLISHED ON JUN 04, 2021 09:54 AM IST
Domestic pharmaceutical major Zydus Cadila has sought the Drug Controller General of India (DCGI) permission recently to undertake clinical trials of the antibodies cocktail.
The treatment candidate, ZRC-3308, was earlier shown to reduce lung damage during animal trials(Reuters file photo. Representative image)
The treatment candidate, ZRC-3308, was earlier shown to reduce lung damage during animal trials(Reuters file photo. Representative image)

Zydus Cadila seeks human trial approval for Covid-19 antibody cocktail

Reuters | , Bengaluru
UPDATED ON MAY 27, 2021 10:34 AM IST
  • The company is seeking permission to conduct early-to late-stage human clinical trials from the Drugs Controller General of India
The phase II study of ZyCoV-D had been conducted in over 1,000 healthy adult volunteers as part of the adaptive Phase I/II dose-escalation, multi-centric, randomised, double-blind placebo-controlled study, the drug firm said.(AFP)
The phase II study of ZyCoV-D had been conducted in over 1,000 healthy adult volunteers as part of the adaptive Phase I/II dose-escalation, multi-centric, randomised, double-blind placebo-controlled study, the drug firm said.(AFP)

Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for Covid-19 vaccine

New Delhi | By Press Trust of India| Posted by Susmita Pakrasi
UPDATED ON JAN 03, 2021 04:35 PM IST
The company will now be initiating Phase III clinical trial in around 30,000 volunteers, Zydus Cadila said in a statement.
In its Covid-19 vaccine development initiative, Zydus has been supported by national biopharma mission, biotechnology industry research assistance council, department of biotechnology, Indian council of medical research, and national institute of virology, Pune. (Image used for representation).(REUTERS PHOTO.)
In its Covid-19 vaccine development initiative, Zydus has been supported by national biopharma mission, biotechnology industry research assistance council, department of biotechnology, Indian council of medical research, and national institute of virology, Pune. (Image used for representation).(REUTERS PHOTO.)

Zydus Cadila seeks Phase 3 clinical trials approval for its Covid-19 vaccine

Hindustan Times, New Delhi | By Rhythma Kaul
UPDATED ON DEC 25, 2020 12:20 AM IST
The trial has been reviewed by an independent Data Safety Monitoring Board (DSMB), and reports have been submitted to Central Drugs Standard Control Organisation (CDSCO) regularly for the update on safety outcome.
PM Modi will visit Ahmedabad’s Zydus Biotech Park, Hyderabad’s Bharat Biotech and Pune’s Serum Institute of India (SII).(PTI image)
PM Modi will visit Ahmedabad’s Zydus Biotech Park, Hyderabad’s Bharat Biotech and Pune’s Serum Institute of India (SII).(PTI image)

PM Modi to visit 3 drug development centres today to review Covid-19 vaccine progress

Hindustan Times, New Delhi | By hindustantimes.com | Edited by Prashasti Singh
UPDATED ON NOV 28, 2020 08:55 AM IST
According to reports, the PM will first visit pharma major Zydus Cadila’s plant around 9.30am. Zydus Cadila had announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D was over and it has commenced phase-II clinical trials from August.
Zydus Cadila said its Pegylated Interferon alpha-2b, PegiHep, was originally approved for Hepatitis C and was launched in the Indian market in 2011.(AFP file photo)
Zydus Cadila said its Pegylated Interferon alpha-2b, PegiHep, was originally approved for Hepatitis C and was launched in the Indian market in 2011.(AFP file photo)

Zydus Cadila completes phase 2 clinical trial in Covid-19 patients with Hepatitis C biological therapy PegiHep

New Delhi | By Press Trust of India | Posted by Deepali Sharma
PUBLISHED ON NOV 12, 2020 03:26 PM IST
Zydus Cadila said it had conducted this study on the approval from the Drugs Controller General of India (DCGI) to investigate the role of Pegylated Interferon alpha-2b for Covid- 19.
The company said it has completed all IND enabling preclinical studies and has filed the IND application to advance this drug candidate towards the clinic.(REUTERS)
The company said it has completed all IND enabling preclinical studies and has filed the IND application to advance this drug candidate towards the clinic.(REUTERS)

Zydus Cadila files investigational new drug application for Covid-19 treatment

New Delhi | By Press Trust of India| Posted by Susmita Pakrasi
UPDATED ON NOV 03, 2020 11:52 AM IST
Zydus Cadila said ZYIL1 will bridge a critical unmet healthcare need in several inflammatory diseases including the current pandemic of Covid-19 and address complications caused by chronic and uncontrolled inflammation.
Photo provided by the Russian Direct Investment Fund (RDIF) shows samples of a vaccine against the coronavirus disease (Covid-19) developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Moscow.(Reuters File Photo)
Photo provided by the Russian Direct Investment Fund (RDIF) shows samples of a vaccine against the coronavirus disease (Covid-19) developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Moscow.(Reuters File Photo)

Results of Covid-19 vaccines’ trial to take a few weeks, says VK Paul

Hindustan Times, New Delhi | By Rhythma Kaul
UPDATED ON AUG 19, 2020 07:49 PM IST
The two Covid-19 vaccine candidates that are in phase I/II human trials are drug maker Zydus Cadila’s ZyCov-D and Bharat Biotech’s Covaxin.
Vials of a COVID-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert.(Reuters File Photo)
Vials of a COVID-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert.(Reuters File Photo)

Govt kick-starts talks to explore Covid-19 vaccine deal

Hindustan Times, New Delhi | By Rhythma Kaul, New Delhi
UPDATED ON AUG 18, 2020 03:49 AM IST
The national vaccine expert group has referred the matter of selection of the right vaccine candidate for use in the country to the Standing Technical Sub-Committee of National Technical Advisory Group on Immunization (NTAGI).
Photo provided by the Russian Direct Investment Fund (RDIF) shows samples of a vaccine against the coronavirus disease (Covid-19) developed by the Gamaleya Research Institute of Epidemiology and Microbiology, in Moscow, Russia.(Reuters File Photo)
Photo provided by the Russian Direct Investment Fund (RDIF) shows samples of a vaccine against the coronavirus disease (Covid-19) developed by the Gamaleya Research Institute of Epidemiology and Microbiology, in Moscow, Russia.(Reuters File Photo)

India eyes global front runners in Covid-19 vaccine plan

Hindustan Times, New Delhi | By Saubhadra Chatterji and Rhythma Kaul, New Delhi
UPDATED ON AUG 17, 2020 03:18 AM IST
According to an official, the National Expert Group on Vaccine Administration will hold its second meeting on Monday and discuss with granular details of Covid-19 vaccine procurement processes and pricing with the heads of several pharma firms, including SII, Bharat Biotech and Zydus Cadila
SHARE
  • 1
  • 2
  • ...
Story Saved